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Abstract 1 
Background: Hypogonadism in boys is one of the commonest conditions encountered in 2 
paediatric endocrinology  3 
Aims: To study variations in management in a contemporary group of boys at a single specialist 4 
centre. 5 
Methods: Retrospective review of case records of all boys treated with testosterone at a tertiary 6 
endocrine service from 2012- 2017. 7 
Results: Of the 358 boys reviewed for hypogonadism, 46 (13%) were initiated on testosterone 8 
therapy at a median age (range) of 14.2 years (12.1, 17.7). Indications for therapy included a 9 
functional delay of puberty that was constitutional in 17 (37%) or related to chronic disease in 10 
10 (22%) or organic hypogonadism due to primary gonadal failure in 7 (15%), multiple 11 
pituitary hormone deficiency in 6 (13%), and isolated hypogonadotrophic hypogonadism in 6 12 
(13%). Of the 46, 40 (89%) were started on intramuscular testosterone, 4 (9%) on oral 13 
testosterone and 1 (2%) on transdermal gel. Of the 19 boys (40%) with organic hypogonadism 14 
requiring long-term therapy, 12 (63%) had assessment of liver function, 6 (32%) had a 15 
haematocrit and 2 (11%) had a DXA scan in the year of commencing treatment. 16 
Conclusions: Testosterone therapy is administered in about 13% of boys reviewed for 17 
hypogonadism and its monitoring requires standardisation. 18 
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Introduction 1 
Delayed puberty in boys is defined as the absence of testicular enlargement over 4ml after the 2 
age of 14 years or greater than 2 SD later than the population mean [1]. It is a common 3 
indication for referral to paediatric endocrine services, affecting approximately 2% of 4 
adolescents [2]. Boys with delayed puberty may present with significant psychosocial distress 5 
secondary to this, as well as long-term health consequences such as osteopaenia [3, 4]. In boys, 6 
hypogonadism can be categorised as functional or organic; common causes of functional 7 
hypogonadism in boys include constitutional delay of puberty and a delay secondary to chronic 8 
disease. These forms of hypogonadism often require short periods of testosterone therapy 9 
unlike organic hypogonadism secondary to conditions such as primary gonadal failure or 10 
hypogonadotrophic hypogonadism when testosterone therapy may be life-long [5]. Existing 11 
guidelines for testosterone replacement in adults recommend monitoring of testosterone levels 12 
during treatment for efficacy as well as for likely complications associated with testosterone 13 
therapy including cardiometabolic compromise, polycythaemia and derangement of liver 14 
enzymes [6]. The frequency of testosterone therapy in boys as well as the extent of variation in 15 
its monitoring has rarely been described [7]. The aim of the current study is to characterise the 16 
group of boys that present with suspected hypogonadism in adolescence and are subsequently 17 
treated with testosterone. 18 
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37 
Patients & Methods  1 
A retrospective review of case notes was conducted of all boys treated with testosterone for 2 
pubertal delay in the Royal Hospital for Children in Glasgow, UK from 2012 to 2017. 3 
Continuous variables are described as median and ranges and inter-group comparison for these 4 
variables was performed by Students T tests or one-way ANOVA as appropriate. Chi square 5 
analysis was performed to compare proportions in different groups. The level of p<0.05 was 6 
considered to be statistically significant and all analyses were performed using Microsoft Excel 7 
version 14.0 (USA) or GraphPad Prism version 4.0 (USA).    8 
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Results  1 
Indications 2 
Over the study period of 5 years, 358 boys, including 175 new referrals, were seen for review 3 
of boys with possible delayed puberty. Of these 358, 46 (13%) were treated with testosterone 4 
at a median age (range) of 14.2 years (12.1, 17.7). A median number of 7 boys (2, 15) were 5 
started on testosterone each year. Indications for treatment were constitutional delayed growth 6 
and puberty (CDGP) in 17 (37%), chronic disease related hypogonadism in 10 (22%), primary 7 
gonadal failure in 7 (15%), multiple pituitary hormone deficiency (MPHD) in 6 (13%), and 8 
isolated hypogonadotrophic hypogonadism in 6 (13%). Of those with chronic disease related 9 
hypogonadism, the underlying diagnosis was Duchenne Muscular Dystrophy in 5 (50%); 10 
Crohns disease in 1 (10%); HIV in 1 (10%); Juvenile Idiopathic Arthritis in 1 (10%); Addisons 11 
disease in 1 (10%) and immune dysregulation in 1 (10%). Age at starting treatment was similar, 12 
regardless of underlying diagnosis, with a median of 14.0 years (13.1, 17.7) in the 27 boys with 13 
a functional delay in puberty due to CDGP or chronic disease versus a median of 13.2 years 14 
(12.1, 17.4) in the 20 boys with organic hypogonadism (p=0.3) (Fig.1). Of the 28 boys with 15 
functional hypogonadism, 24, (86%) received only one 3 month course of testosterone whereas 16 
four received a 6-month course. All of the 19 boys with organic hypogonadism remain on 17 
current treatment. 18 
 19 
Testosterone Therapy  20 
Of the 46 boys, 3 (7%) were treated with oral testosterone; 1 (2%) with oral and intramuscular 21 
testosterone depot (IM); 1 (2%) with transdermal testosterone gel and IM and the rest (89%) 22 
with IM alone. Of the 4 boys on oral testosterone, 1 (25%) was on testosterone undecanoate 23 
40mg on alternate days and the rest (75%) were on testosterone undecanoate 40mg daily. Of 24 
the 43 boys on IM, 2 (5%) were on 1g testosterone undecanoate as Nebido and the rest (95%) 25 
were on varying doses of testosterone enanthate as Sustanon (median starting dose 100 (range 26 
50-250 mg)).  27 
 28 
Investigations at Initiation of Testosterone Therapy 29 
Of the 46 boys who were treated with testosterone, 40 (85%) had a bone age assessment, 12 30 
(26%) had liver function tests (LFT), 6 (13%) had a haematocrit and 6 (13%) had an assessment 31 
of bone density by DXA within the year prior to starting testosterone. Of the 19 boys with 32 
organic hypogonadism, 12 (63%) had liver function tests; 6 (32%) had a haematocrit and 2 33 
(11%) had a DXA scan prior to commencing treatment (Fig.2). 34 
 35 
Monitoring of Testosterone Therapy 36 
 During therapy, of the 46 boys, LFTs were assessed in 6 (13%), blood pressure was recorded 1 
in 5 (11%) and a haematocrit was assessed in 3 (6%).  In those who had LFTs or haematocrit 2 
performed, the indication for therapy was chronic disease related hypogonadism. Of the 6 boys 3 
who had LFTs, 4 (67%) had raised transaminases, which had previously been normal. None of 4 
the boys had any changes in testosterone dose based on the results of these investigations. Of 5 
the 46 boys, two (4%) reported a change in behaviour on testosterone therapy with increased 6 
aggression but did not require any change to treatment secondary to this.  One of these boys 7 
had primary hypogonadism secondary to bilateral anorchia and was treated with IM 8 
testosterone therapy. The other had hypogonadotrophic hypogonadism and was on a treatment 9 
schedule with oral testosterone undecanoate.  10 
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Discussion 1 
This study provides useful insight into the management of delayed puberty in boys, 2 
demonstrating that just over 10% of boys referred to a clinical paediatric endocrinology service 3 
receive testosterone therapy for induction of puberty. In actual numbers, this amounted to less 4 
than 10 cases per year. It is also interesting to note that despite the availability of several routes 5 
for administering testosterone therapy, the intramuscular depot form of testosterone remains 6 
the most popular. This may be related to difficulties in ensuring a continuous supply of oral 7 
testosterone undecanoate and a lack of an evidence base for the commonly available forms of 8 
transdermal testosterone. Approximately 60% of the cases that required testosterone therapy 9 
had a functional delay of puberty and required short-term therapy and the remainder had 10 
organic pathology requiring long-term testosterone therapy. Whilst categorising cases between 11 
functional and organic provides some insight into the indications of testosterone therapy, it is 12 
acknowledged that overlaps can exist within this classification. Although CDGP was the 13 
commonest presentation of functional delayed puberty [1, 8], in our cohort there was a high 14 
prevalence of hypogonadism secondary to chronic disease. Poor growth and delayed puberty 15 
are often associated with chronic disease [9, 10]. The frequency of testosterone therapy in these 16 
adolescents may depend on awareness and threshold for referral from clinicians who manage 17 
the boys’ primary disease. 18 
 19 
In adults, it is considered good practice to perform regular biochemical and haematological 20 
assessments to assess safety and efficacy of long term therapy [6].  In boys requiring 21 
testosterone therapy, previous studies have shown variable efficacy and pharmacodynamic 22 
profiles [11, 12]. Systematic monitoring of safety and efficacy other than assessment of 23 
virilisation and growth was not performed in the cohort of boys studied here and there is little 24 
evidence that this is performed elsewhere in similar cohorts [7].  Boys with chronic disease 25 
related hypogonadism were more likely in our cohort to have some form of monitoring 26 
probably because of the increased need for surveillance of their underlying condition. The lack 27 
of existing guidance for monitoring may be due to the fact that most boys require testosterone 28 
for a short period. In our cohort, over 50% of boys requiring testosterone did not have primary 29 
gonadal failure or a condition such as MPHD or hypogonadotrophic hypogonadism. Although 30 
in our cohort, testosterone therapy was well tolerated with only 4% of boys reporting a clinical 31 
adverse effect that could be attributed to the therapy there were some cases that displayed a 32 
derangement in liver function. Of note, this was observed in those who had a functional delay 33 
in puberty and were receiving testosterone therapy for a short period. Given that the indications 34 
and goals for testosterone therapy in adolescence are more variable than in adults, guidance for 35 
monitoring of therapy in adults cannot be simply replicated in adolescents and may be 36 
influenced by the underlying condition and/or the duration of therapy. 37 
 1 
In conclusion, testosterone therapy for hypogonadism in boys is rare and given that it may be 2 
associated with adverse events, there is a need to consider clinical guidance that can be applied 3 
to monitor safety as well as efficacy of therapy in this age group.  4 
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Legend To Figures 1 
Figure 1. Age at starting testosterone therapy according to underlying diagnosis. The black 2 
line represents the median age. Abbreviations: CDGP: chronic disease related hypogonadism; 3 
hypog hypog: hypogonadotrophic hypogonadism; MPHD: multiple pituitary hormone 4 
disease.  5 
 6 
Figure 2. Investigations performed in the year prior to treatment according to underlying 7 
diagnosis. Abbreviations: LFTs: liver function tests; CDGP: chronic disease related 8 
hypogonadism; hypog hypog: hypogonadotrophic hypogonadism; MPHD: multiple pituitary 9 
hormone disease. 10 
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